3rd Quarter - Termination
PHARMATHENE, INC for PHARMATHENE, INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Firm
Client
Income
—
Expenses
$207,464
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Jul 1, 2008
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 23, 2008 | $207,464 | Replaced |
| 3rd Quarter - Termination (this page) | Aug 25, 2009 | $207,464 | Replaced |
| 3rd Quarter - Amendment | Oct 20, 2009 | $207,464 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Health & Human Services (HHS) anthrax vaccine and antitoxin. Avanced research and development. BARDA funding. Project Bioshield. Biodefense
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK EDWARD COOKE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.